

Diana Giannarelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5308048/diana-giannarelli-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

427
papers

13,394
citations

57
h-index

99
g-index

451
ext. papers

15,643
ext. citations

4.9
avg, IF

5.96
L-index

#	Paper	IF	Citations
427	Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study.. <i>International Immunopharmacology</i> , 2022 , 108, 108774	5.8	2
426	A prospective study assessing the pattern of response of local disease at DCE-MRI after salvage radiotherapy for prostate cancer.. <i>Clinical and Translational Radiation Oncology</i> , 2022 , 35, 21-26	4.6	1
425	A Prospective Study Assessing the Post-Prostatectomy Detection Rate of a Presumed Local Failure at mpMR with Either CuCl or CuPSMA PET/CT. <i>Cancers</i> , 2021 , 13,	6.6	3
424	Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma. <i>EXCLI Journal</i> , 2021 , 20, 1152-1169	2.4	1
423	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. <i>BMJ Open</i> , 2021 , 11, e049128	3	1
422	Palliative care organization and staffing models in residential hospices: Which makes the difference?. <i>International Journal of Nursing Studies</i> , 2021 , 126, 104135	5.8	
421	A Clue to Better Select Chronic Lymphocytic Leukemia Patients with Optimal Response to BNT162b2 mRNA COVID-19 Vaccine. <i>Blood</i> , 2021 , 138, 3740-3740	2.2	1
420	Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. <i>Molecular Cancer</i> , 2021 , 20, 151	42.1	1
419	Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. <i>Life</i> , 2021 , 11,	3	3
418	Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers. <i>Vaccines</i> , 2021 , 9,	5.3	14
417	The right immune-modulation at the right time: thymosin α 1 for prevention of severe COVID-19 in cancer patients. <i>Future Oncology</i> , 2021 , 17, 1097-1104	3.6	1
416	Antiseizure medication in patients with Glioblastoma- a collaborative cohort study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021 , 87, 107-113	3.2	1
415	Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. <i>Tumori</i> , 2021 , 3008916211004733	1.7	1
414	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2) 2021 , 9,		3
413	Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. <i>Cancers</i> , 2021 , 13,	6.6	3
412	Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021 , 11, 684110	5.3	3
411	Major Differences in Lymphocyte Subpopulations Between Cerebrospinal Fluid and Peripheral Blood in Non-Hodgkin Lymphoma Without Leptomeningeal Involvement: Flow Cytometry Evidence of a Cerebral Lymphatic System. <i>Frontiers in Oncology</i> , 2021 , 11, 685786	5.3	1

410	Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. <i>Vaccines</i> , 2021 , 9,	5.3	11
409	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. <i>Clinical Cancer Research</i> , 2021 , 27, 4737-4745	12.9	8
408	Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. <i>EClinicalMedicine</i> , 2021 , 36, 100928	11.3	45
407	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021 , 13,	6.6	5
406	Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis. <i>Leukemia</i> , 2021 , 35, 615-618	10.7	5
405	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia</i> , 2021 , 35, 737-746	10.7	32
404	Idiopathic acute pancreatitis: a single-center investigation of clinical and biochemical features. <i>Internal and Emergency Medicine</i> , 2021 , 16, 93-99	3.7	
403	Prevalence and risk factors of delirium in the intensive care unit: An observational study. <i>Nursing in Critical Care</i> , 2021 , 26, 156-165	2.7	3
402	Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021 , 39, 141-144	1.3	1
401	A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system. <i>Supportive Care in Cancer</i> , 2021 , 29, 3219-3233	3.9	3
400	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. <i>Journal of Translational Medicine</i> , 2021 , 19, 17	8.5	4
399	Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 56, 498-504	2.4	1
398	Low Frequency of Acute Pancreatitis in Hospitalized COVID-19 Patients. <i>Pancreas</i> , 2021 , 50, 393-398	2.6	3
397	Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 977-982	2.2	0
396	Safety of outpatient stem cell mobilization with low- or intermediate-dose cyclophosphamide in newly diagnosed multiple myeloma patients. <i>European Journal of Haematology</i> , 2021 , 107, 566-572	3.8	1
395	FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021 , 75, 351-362	13.4	10
394	Italian nursing students' attitudes towards care of the dying patient: A multi-center descriptive study. <i>Nurse Education Today</i> , 2021 , 104, 104991	3.7	1
393	Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 969-976	35.1	9

392	Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution. <i>Clinical Cancer Research</i> , 2021 ,	12.9	14
391	Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 2020 , 8,		16
390	Inequity in palliative care service full utilisation among patients with advanced cancer: a retrospective Cohort study. <i>Acta Oncologica</i> , 2020 , 59, 620-627	3.2	5
389	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. <i>Immunotherapy</i> , 2020 , 12, 151-159	3.8	8
388	Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. <i>Journal of Translational Medicine</i> , 2020 , 18, 121	8.5	14
387	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , 2020 , 10, 202	5.3	3
386	Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. <i>Future Oncology</i> , 2020 , 16, 1629-1637	3.6	2
385	Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study). <i>Frontiers in Neurology</i> , 2020 , 11, 592	4.1	12
384	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. <i>Cancers</i> , 2020 , 12,	6.6	14
383	Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions. <i>Clinical and Translational Radiation Oncology</i> , 2020 , 21, 91-97	4.6	2
382	Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 187-194	1.7	17
381	Multimodal pathway for brain tumor-related epilepsy patients: Observational study. <i>Acta Neurologica Scandinavica</i> , 2020 , 141, 450-462	3.8	2
380	Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2020 , 104, 512-515	3.8	3
379	Perampanel in brain tumor-related epilepsy: Observational pilot study. <i>Brain and Behavior</i> , 2020 , 10, e01612	3.4	14
378	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy 2020 , 8,		13
377	The prevalence of musculoskeletal disorders and low back pain among Italian nurses: An observational study. <i>Acta Biomedica</i> , 2020 , 91, e2020003	3.2	6
376	Diabetes and diabetic retinopathy in patients undergoing cataract surgery: a prevalence study-DiCat study report #2. <i>Acta Diabetologica</i> , 2020 , 57, 645-650	3.9	0
375	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020 , 140, 59-64	5.9	22

374	Comparison of venetoclax plus rituximab with B-cell receptor inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia: a systematic review and network Meta-analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 955-958	1.9	3
373	Early-onset versus late-onset Crohn's disease: An Italian cohort study. <i>United European Gastroenterology Journal</i> , 2020 , 8, 52-58	5.3	3
372	Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression $\geq 1\%$. <i>Journal of Immunotherapy</i> , 2020 , 43, 299-306	5	10
371	Prevalence, incidence and associated factors of pressure injuries in hospices: A multicentre prospective longitudinal study. <i>International Journal of Nursing Studies</i> , 2020 , 111, 103760	5.8	5
370	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968463	5.4	7
369	Quality of life and disability of chronic non-cancer pain in adults patients attending pain clinics: A prospective, multicenter, observational study. <i>Applied Nursing Research</i> , 2020 , 56, 151332	1.8	4
368	HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. <i>Cells</i> , 2020 , 9,	7.9	17
367	Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy. <i>Immunotherapy</i> , 2020 , 12, 1139-1148	3.8	6
366	Effect of Brivaracetam on Efficacy and Tolerability in Patients With Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study. <i>Frontiers in Neurology</i> , 2020 , 11, 813	4.1	7
365	Prevalence of diabetes and diabetic macular edema in patients undergoing senile cataract surgery in Italy: The Diabetes and CATaract study. <i>European Journal of Ophthalmology</i> , 2020 , 30, 315-320	1.9	9
364	Cost-effectiveness in transient hypocalcemia post-thyroidectomy. <i>Head and Neck</i> , 2019 , 41, 3940-3947	4.2	6
363	Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 7312-7319	12.9	80
362	Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study. <i>Radiation Oncology</i> , 2019 , 14, 23	4.2	5
361	The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy. <i>Current Problems in Cancer</i> , 2019 , 43, 100479	2.3	1
360	Risk factors for a difficult intravenous access: A multicentre study comparing nurses' beliefs to evidence. <i>Journal of Clinical Nursing</i> , 2019 , 28, 3492-3504	3.2	5
359	State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 87-90	7	15
358	Epidemiology of Chronic Pain in the Latium Region, Italy: A Cross-Sectional Study on the Clinical Characteristics of Patients Attending Pain Clinics. <i>Pain Management Nursing</i> , 2019 , 20, 373-381	2.5	20
357	The Effectiveness of the Sport "Dragon Boat Racing" in Reducing the Risk of Lymphedema Incidence: An Observational Study. <i>Cancer Nursing</i> , 2019 , 42, 323-331	2.6	4

356	Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 423-430	2	16
355	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019 , 25, 3839-3846	12.9	90
354	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program 2019 , 7, 99		71
353	BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e57-e59	8.9	13
352	Oral Hygiene Care in Patients With Advanced Disease: An Essential Measure to Improve Oral Cavity Conditions and Symptom Management. <i>American Journal of Hospice and Palliative Medicine</i> , 2019 , 36, 815-819	2.6	9
351	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019 , 123, 98-105	5.6	48
350	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019 , 39, 4265-4271	2.3	19
349	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , 2019 , 134, 121-126	5.9	1
348	Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach. <i>Journal of Oncology Practice</i> , 2019 , 15, 460-461	3.1	2
347	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019 , 123, 72-80	7.5	34
346	Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol. <i>BMJ Open</i> , 2019 , 9, e031485	3	6
345	Correlation between Work Engagement and Burnout among Registered Nurses: an Italian hospital survey. <i>Professioni Infermieristiche</i> , 2019 , 72, 42-49	1	5
344	Upfront Therapy with Ibrutinib Results in a Longer Progression-Free Survival Independently of IGHV Mutational Status and Del(11q) in CLL Patients. Results of a Comprehensive Review and Meta-Analysis. <i>Blood</i> , 2019 , 134, 5469-5469	2.2	
343	Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability. <i>Blood</i> , 2019 , 134, 5555-5555	2.2	
342	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 7351-7362	12.9	33
341	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019 , 24, e1165-e1171	5.7	23
340	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. <i>Cancers</i> , 2019 , 11,	6.6	26
339	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 2019 , 7, 316		56

338	The Effect of Docosahexaenoic Acid and Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma. <i>Integrative Cancer Therapies</i> , 2019 , 18, 1534735419888584	3	5
337	Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study. <i>Clinical Neuropharmacology</i> , 2019 , 42, 167-171	1.4	1
336	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 129, 35-40	5.9	77
335	IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019 , 33, 1519-1522	10.7	7
334	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. <i>British Journal of Cancer</i> , 2019 , 120, 57-62	8.7	40
333	Peripherally inserted central catheter, midline, and "short" midline in palliative care: Patient-reported outcome measures to assess impact on quality of care. <i>Journal of Vascular Access</i> , 2019 , 20, 475-481	1.8	3
332	Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis. <i>International Journal of Neuroscience</i> , 2019 , 129, 593-597	2	18
331	The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1644-1649	1.9	3
330	A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 845-847	1.9	6
329	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2018 , 14, 353-361	3.6	3
328	Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2018 , 55, 202-208	4	4
327	Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. <i>Transfusion</i> , 2018 , 58, 1143-1148	2.9	1
326	Inflatable Penile Prosthesis Placement, Scratch Technique and Postoperative Vacuum Therapy as a Combined Approach to Definitive Treatment of Peyronie's Disease. <i>Journal of Urology</i> , 2018 , 200, 642-647	2.5	24
325	BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1051-1054	4.4	2
324	Supracricoid partial laryngectomy for radiorecurrent laryngeal cancer: a systematic review of the literature and meta-analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018 , 275, 1671-1680	3.5	8
323	Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. <i>International Journal of Biological Markers</i> , 2018 , 1724600818754763	2.8	
322	Adherence to Oral Administration of Endocrine Treatment in Patients With Breast Cancer: A Qualitative Study. <i>Cancer Nursing</i> , 2018 , 41, E57-E63	2.6	14
321	Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. <i>Blood</i> , 2018 , 131, 365-368	2.2	11

320	Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 77-83	5.4	5
319	Prospective evaluation of metabolic syndrome and its features in a single-center series of hematopoietic stem cell transplantation recipients. <i>Annals of Hematology</i> , 2018 , 97, 2471-2478	3	3
318	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018 , 100, 126-134	7.5	65
317	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab 2018 , 6, 74		166
316	T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. <i>Breast</i> , 2018 , 41, 137-143	3.6	26
315	Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 79	22.4	22
314	Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2018 , 97, 2005-2008	3	13
313	Association between Helicobacter pylori infection and vulvar lichen sclerosus: a clinical comparative study. <i>European Journal of Dermatology</i> , 2018 , 28, 226-227	0.8	1
312	Estrogen treatment in infertile women with premature ovarian insufficiency in transitional phase: a retrospective analysis. <i>Journal of Assisted Reproduction and Genetics</i> , 2018 , 35, 475-482	3.4	3
311	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncolimmunology</i> , 2018 , 7, e1405206	7.2	27
310	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018 , 10, S1564-S1580	2.6	35
309	Impact of a goal-directed fluid therapy on length of hospital stay and costs of hepatobiliarypancreatic surgery: a prospective observational study. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 1171-1179	2.1	1
308	Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. <i>Tumor Biology</i> , 2018 , 40, 1010428318815047	2.9	4
307	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018 , 8, 463	5.3	17
306	mutation and DNA repair and synthesis genes in non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018 , 9, 689-696	1.6	4
305	Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. <i>Integrative Cancer Therapies</i> , 2018 , 17, 1115-1124	3.24	18
304	Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. <i>Postgraduate Medical Journal</i> , 2018 , 94, 566-570	2	3
303	Influenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. <i>Immunotherapy</i> , 2018 , 10, 1229-1239	3.8	22

302	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1146-1155	8.9	57
301	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. <i>Future Oncology</i> , 2018 , 14, 1347-1354	3.6	7
300	Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 451-460	35.1	129
299	Factors affecting difficult peripheral intravenous cannulation in adults: a prospective observational study. <i>Journal of Clinical Nursing</i> , 2017 , 26, 1074-1084	3.2	30
298	The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e661-e666	3.3	35
297	Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase. <i>American Journal of Hematology</i> , 2017 , 92, E91-E93	7.1	10
296	Meeting report: Vitiligo Global Issues Consensus Conference Workshop "Outcome measurement instruments" and Vitiligo International Symposium, Rome, Nov 30-Dec 3rd. <i>Pigment Cell and Melanoma Research</i> , 2017 , 30, 436-443	4.5	6
295	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. <i>Onc Immunology</i> , 2017 , 6, e1283462	7.2	21
294	The course of cancer related fatigue up to ten years in early breast cancer patients: What impact in clinical practice?. <i>Breast</i> , 2017 , 34, 44-52	3.6	44
293	Zonisamide in Brain Tumor-Related Epilepsy: An Observational Pilot Study. <i>Clinical Neuropharmacology</i> , 2017 , 40, 113-119	1.4	7
292	Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. <i>Epilepsy and Behavior</i> , 2017 , 73, 83-89	3.2	29
291	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. <i>Onc Immunology</i> , 2017 , 6, e1323618	7.2	31
290	Laser-assisted hatching of human embryos: may two alternative approaches (thinning versus drilling) impact on implant rate?. <i>Lasers in Medical Science</i> , 2017 , 32, 1663-1666	3.1	8
289	The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1971-1976	4.9	26
288	Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer. <i>Head and Neck</i> , 2017 , 39, 1761-1769	4.2	17
287	The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 975-980	1.5	38
286	Chronic lymphocytic leukemia and prognostic models: A bridge between clinical and biological markers. <i>American Journal of Hematology</i> , 2017 , 92, E135-E137	7.1	6
285	P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1336-S1337	8.9	2

284	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2017 , 15, 244	8.5	55
283	Short course hypofractionated whole breast irradiation after conservative surgery: a single institution phase II study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 191	12.8	3
282	Propolis in the prevention of oral mucositis in breast cancer patients receiving adjuvant chemotherapy: A pilot randomised controlled trial. <i>European Journal of Cancer Care</i> , 2017 , 26, e12757	2.4	26
281	Procedural Pain in Palliative Care: Is It Breakthrough Pain? A Multicenter National Prospective Study to Assess Prevalence, Intensity, and Treatment of Procedure-related Pain in Patients With Advanced Disease. <i>Clinical Journal of Pain</i> , 2017 , 33, 707-714	3.5	6
280	HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence. <i>Journal of NeuroVirology</i> , 2017 , 23, 147-151	3.9	5
279	Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. <i>Bone Marrow Transplantation</i> , 2017 , 52, 154-156	4.4	19
278	The introduction of the absolute risk for the detection of fetal aneuploidies in the first-trimester screening. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017 , 30, 1249-1253	2	10
277	Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI). <i>Leukemia and Lymphoma</i> , 2017 , 58, 1736-1739	1.9	14
276	Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?. <i>Future Oncology</i> , 2017 , 13, 2791-2797	3.6	19
275	Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up. <i>Tumori</i> , 2017 , 103, 255-260	1.7	4
274	Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center. <i>PLoS ONE</i> , 2017 , 12, e0180470	3.7	15
273	Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study. <i>Oncotarget</i> , 2017 , 8, 64481-64489	3.3	15
272	Improving cancer patients' knowledge about totally implantable access port: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2016 , 24, 833-841	3.9	6
271	"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 119-264	2.4	4
270	Some considerations about the value based pricing in oncology: an analysis on metastatic first line medicinal products. <i>Global & Regional Health Technology Assessment</i> , 2016 , 3, 9-15	0.2	1
269	Preperitoneal Continuous Infusion of Local Anesthetics: What Is the Impact on Surgical Wound Infections in Humans?. <i>Pain Medicine</i> , 2016 , 17, 582-589	2.8	3
268	Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. <i>Annals of Oncology</i> , 2016 , 27, 732-8	10.3	229
267	Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. <i>OncImmunity</i> , 2016 , 5, e1071007	7.2	18

266	Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy. <i>Gene</i> , 2016 , 577, 227-35	3.8	24
265	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , 2016 , 21, 283-91	5.7	35
264	Antitumor Activity of BRAF Inhibitor and IFN γ Combination in BRAF-Mutant Melanoma. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	29
263	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 254-63	7	1
262	Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3067-3067	2.2	4
261	Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e12019-e12019	2.2	1
260	Tremelimumab and durvalumab (MEDI4736) combination for first and second-line treatment of mesothelioma patients: The NIBIT-MESO-1 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS8575-TPS8575	2.2	3
259	A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS9595-TPS9595	2.2	1
258	"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016 , 7, 17932-44	3.3	26
257	Propensity score analysis investigating the role of hormonal maintenance (HM) for advanced breast carcinoma with luminal subtype (ABC-Lum): Implication for prognostic modeling, post-progression and conditional survival (PPS/CS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 545-545	2.2	
256	Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 3187-3187	2.2	
255	Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma. <i>Journal of Thoracic Disease</i> , 2016 , 8, 386-95	2.6	4
254	Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E2118-21	4.2	23
253	Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. <i>Breast</i> , 2016 , 29, 24-30	3.6	8
252	Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016 , 35, 193	12.8	5
251	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. <i>Lung Cancer</i> , 2016 , 95, 82-7	5.9	15
250	Comparison of Two Questionnaires on Informed Consent in "Marginal" Donor Liver. <i>Transplantation Proceedings</i> , 2016 , 48, 359-61	1.1	1
249	Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. <i>British Journal of Cancer</i> , 2016 , 115, 1280-1284	8.7	29

248	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. <i>American Journal of Hematology</i> , 2016 , 91, 1090-1095	7.1	43
247	A novel LAMP2 mutation associated with severe cardiac hypertrophy and microvascular remodeling in a female with Danon disease: a case report and literature review. <i>Cardiovascular Pathology</i> , 2016 , 25, 423-31	3.8	24
246	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016 , 231, 2541-7	7	10
245	Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model. <i>European Journal of Haematology</i> , 2016 , 96, 72-7	3.8	13
244	Adherence to hormone therapy in women with breast cancer: a quantitative study. <i>Professioni Infermieristiche</i> , 2016 , 69, 113-21	1	3
243	Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. <i>World Journal of Urology</i> , 2015 , 33, 1419-28	4	16
242	Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e55-60	2	3
241	Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study. <i>American Journal of Obstetrics and Gynecology</i> , 2015 , 212, 335.e1-7	6.4	11
240	Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma: younger and older patients should be equally treated. A prospective study and literature review. <i>Gynecologic Oncology</i> , 2015 , 137, 373-9	4.9	14
239	Hereditary hemochromatosis type 1 phenotype modifiers in Italian patients. The controversial role of variants in HAMP, BMP2, FTL and SLC40A1 genes. <i>Blood Cells, Molecules, and Diseases</i> , 2015 , 55, 71-5	2.1	18
238	Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 301-9	35.1	148
237	Association between anemia and multiple sclerosis. <i>European Neurology</i> , 2015 , 73, 233-237	2.1	10
236	Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma. <i>Experimental Hematology and Oncology</i> , 2015 , 4, 17	7.8	6
235	Cognitive rehabilitation training in patients with brain tumor-related epilepsy and cognitive deficits: a pilot study. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 419-26	4.8	34
234	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>Oncolimmunology</i> , 2015 , 4, e1008842	7.2	50
233	Interferon- β therapy and risk of thrombocytopenia in multiple sclerosis patients. <i>Neurological Sciences</i> , 2015 , 36, 2263-8	3.5	9
232	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 93, 50-9	7	11
231	Elaboration of a nomogram to predict non sentinel node status in breast cancer patients with positive sentinel node, intra-operatively assessed with one step nucleic acid amplification method. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 136	12.8	12

230	Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. <i>American Journal of Hematology</i> , 2015 , 90, 970-4	7.1	2
229	Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 6177-83	4.4	16
228	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015 , 10, e0130142	3.7	339
227	Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. <i>British Journal of Cancer</i> , 2015 , 112, 1904-10	8.7	156
226	Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2015 , 41, 262-70	14.4	12
225	Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. <i>Future Oncology</i> , 2015 , 11, 431-8	3.6	15
224	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Annals of Oncology</i> , 2015 , 26, 798-803	10.3	100
223	A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2015 , 19, 722-9	3.3	81
222	Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis. <i>Blood</i> , 2015 , 126, 498-498	2.2	1
221	Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. <i>Clinical Lung Cancer</i> , 2014 , 15, 86-92	4.9	34
220	Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. <i>Gastric Cancer</i> , 2014 , 17, 718-24	7.6	18
219	Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014 , 28, 642-8	10.7	48
218	Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. <i>British Journal of Haematology</i> , 2014 , 167, 224-32	4.5	22
217	A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL). <i>International Journal of Hematology</i> , 2014 , 100, 290-5	2.3	5
216	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 675-83	7.4	205
215	Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2014 , 210, 363.e1-363.e10	6.4	43
214	Oncological outcome and prognostic factors in malignant parotid tumours. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2014 , 42, 59-65	3.6	17
213	Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 950-6	3.6	26

212	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 599-607	4.4	32
211	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>OncolImmunology</i> , 2014 , 3, e28780	7.2	259
210	Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines. <i>Expert Review of Hematology</i> , 2014 , 7, 691-5	2.8	7
209	Reference charts for fetal corpus callosum length: a prospective cross-sectional study of 2950 fetuses. <i>Journal of Ultrasound in Medicine</i> , 2014 , 33, 1065-78	2.9	30
208	Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas. <i>BioMed Research International</i> , 2014 , 2014, 351252	3	8
207	MP55-11 DEVELOPMENT AND EXTERNAL VALIDATION OF NOMOGRAMS PREDICTING DISEASE-FREE AND CANCER SPECIFIC SURVIVAL AFTER RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2014 , 191,	2.5	2
206	Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014 , 40, 847-56	14.4	15
205	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 135-45	7	11
204	A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7531-7531	2.2	6
203	Retrospective study evaluating the performance of a first-trimester combined screening for trisomy 21 in an Italian unselected population. <i>Journal of Prenatal Medicine</i> , 2014 , 8, 50-6		2
202	Do Pan-negative/never-smoker (NS) lung cancer patients (pts) represent a new distinct subgroup? Data from a single-institution experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19054-e19054	2.2	
201	Exclusion of SERUM Thymidine Kinase Does NOT Reduce the Predictive VALUE of a Comprehensive Prognostic INDEX in Chonic Lymphocytic Leukemia. Results of an External Validation on a Prospective Cohort of Patients with EARLY Disease. <i>Blood</i> , 2014 , 124, 4692-4692	2.2	
200	FCR (Fludarabine, Cyclophosphamide, Rituximab) Followed By 90yttrium Ibritumomab Tiuxetan for the Treatment of Relapsed Grades 1 and 2 Follicular Lymphoma. Long Term Efficacy and Safety Results of 9 Cases. <i>Blood</i> , 2014 , 124, 5452-5452	2.2	
199	Features and organization of Pain Centers in the Lazio Region, Italy, in 2011. <i>Annali Di Igiene: Medicina Preventiva E Di Comunita</i> , 2014 , 26, 367-79	0.9	
198	Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 471-6	3.3	19
197	FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 67	12.8	16
196	Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 49	12.8	13
195	Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10mg/kg within an expanded access programme. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1021-8	7.4	103

194	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis. <i>Leukemia Research</i> , 2013 , 37, 943-7	2.7	7
193	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2013 , 14, 1104-1111	21.7	262
192	A preliminary European Liver and Intestine Transplant Association-European Liver Transplant Registry study on informed recipient consent and extended criteria liver donation. <i>Transplantation Proceedings</i> , 2013 , 45, 2613-5	1.1	18
191	Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 119-23	4.4	28
190	Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 200-5	5.1	14
189	Evaluation of renal function under controlled hypotension in zero ischemia robotic assisted partial nephrectomy. <i>Kidney and Blood Pressure Research</i> , 2013 , 38, 181-5	3.1	8
188	External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2013 , 119, 1177-85	6.4	12
187	Clinical experience with ipilimumab 10mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 82	12.8	16
186	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. <i>OncoTargets and Therapy</i> , 2013 , 6, 1761-9	4.4	7
185	Effect of vaginally administered DHA fatty acids on pregnancy outcome in high risk pregnancies for preterm delivery: a double blinded randomised controlled trial. <i>Journal of Prenatal Medicine</i> , 2013 , 7, 42-5		4
184	Could a biomarkers-based patients' selection help to plan a clinical trial with targeted agents (TA) for metastatic renal cell carcinoma (mRCC)? Interaction and power analysis of randomized trials (RCTs).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 399-399	2.2	
183	Benefit of chemotherapy after third line and evaluation of post-progression survival (PPS) in metastatic breast cancer (MBC): A single institution study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e11517- e 11517		2.2
182	MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 4172-4172	2.2	
181	Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). <i>Leukemia Research</i> , 2012 , 36, 443-7	2.7	19
180	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. <i>Cancer</i> , 2012 , 118, 1523-32	6.4	32
179	Laparoscopic and robotic partial nephrectomy without renal ischaemia for tumours larger than 4 cm: perioperative and functional outcomes. <i>World Journal of Urology</i> , 2012 , 30, 671-6	4	31
178	Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. <i>Future Oncology</i> , 2012 , 8, 1193-7	3.6	4
177	Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. <i>BMC Cancer</i> , 2012 , 12, 482	4.8	18

176	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. <i>Journal of Translational Medicine</i> , 2012 , 10, 107	8.5	93
175	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology</i> , 2012 , 13, 879-86	21.7	232
174	Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. <i>Lung Cancer</i> , 2012 , 78, 81-6	5.9	59
173	IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012 , 31, 17	12.8	17
172	Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. <i>Annals of Oncology</i> , 2012 , 23, 695-700	10.3	138
171	A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. <i>Annals of Oncology</i> , 2012 , 23, 1121-1129	10.3	8
170	BOTH MD Anderson Cancer Center MODEL and German Score Work in Predicting Time to First Treatment in EARLY Chronic Lymphocytic Leukemia: Results of an External Validation Analysis. <i>Blood</i> , 2012 , 120, 3934-3934	2.2	
169	Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. <i>European Journal of Surgical Oncology</i> , 2011 , 37, 148-54	3.6	102
168	Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011 , 35, 1112-6	5.5	8
167	Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 661-7	3.5	29
166	Long-term results of a randomized trial on the sequencing of radiotherapy and chemotherapy in breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 238-44	2.7	13
165	Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. <i>Haematologica</i> , 2011 , 96, 277-83	6.6	41
164	Extended criteria liver donation and transplant recipient consent: the European experience. <i>Transplantation Proceedings</i> , 2011 , 43, 971-3	1.1	10
163	Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 467-77	7.4	72
162	Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 687-93	3.5	8
161	Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1405-12	3.5	14
160	A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011 , 30, 39	12.8	20
159	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011 , 30, 54	12.8	28

158	Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. <i>Annals of Oncology</i> , 2011 , 22, 2277-85	10.3	66
157	A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study. <i>Oncology</i> , 2011 , 81, 230-6	3.6	6
156	Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. <i>Annals of Oncology</i> , 2011 , 22, 625-630	10.3	118
155	VITAMIN D Insufficiency Affects Time to FIRST TREATMENT (TFT) In EARLY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). <i>Blood</i> , 2011 , 118, 4601-4601	2.2	
154	The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. <i>Haematologica</i> , 2010 , 95, 464-9	6.6	31
153	Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. <i>Neurology</i> , 2010 , 74, 762-6	6.5	148
152	Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. <i>BMC Cancer</i> , 2010 , 10, 675	4.8	15
151	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010 , 29, 58	12.8	41
150	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 391-7	3.5	23
149	Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. <i>BMC Cancer</i> , 2010 , 10, 22	4.8	89
148	Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2010 , 85, 314-20	3.8	22
147	Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. <i>Breast Journal</i> , 2010 , 16, 66-72	1.2	8
146	Response: Re: Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 898-899	9.7	9
145	Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2009 , 83, 208-14	3.8	8
144	Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. <i>Cancer</i> , 2009 , 115, 3446-56	6.4	60
143	Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. <i>Lung Cancer</i> , 2009 , 63, 50-7	5.9	37
142	A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. <i>Lung Cancer</i> , 2009 , 66, 365-71	5.9	71
141	Targeting targeted agents: open issues for clinical trial design. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009 , 28, 66	12.8	15

140	Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009 , 28, 35	12.8	7
139	Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009 , 28, 34	12.8	18
138	Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines. <i>Anticancer Research</i> , 2009 , 29, 1841-5	2.3	4
137	Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment. <i>In Vivo</i> , 2009 , 23, 441-6	2.3	3
136	Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. <i>Breast</i> , 2008 , 17, 499-505	3.6	43
135	Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008 , 27, 39	12.8	31
134	Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1707-16	9.7	1043
133	A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. <i>Oncology</i> , 2008 , 75, 175-81	3.6	11
132	Effectiveness of continuous wound infusion of 0.5% ropivacaine by On-Q pain relief system for postoperative pain management after open nephrectomy. <i>British Journal of Anaesthesia</i> , 2008 , 101, 841-7	5.4	105
131	Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. <i>Breast Cancer Research and Treatment</i> , 2008 , 109, 231-9	4.4	119
130	Outcome and tolerability of topiramate in brain tumor associated epilepsy. <i>Journal of Neuro-Oncology</i> , 2008 , 86, 61-70	4.8	62
129	Metastases to the cerebellum. Results and prognostic factors in a consecutive series of 44 operated patients. <i>Journal of Neuro-Oncology</i> , 2008 , 88, 331-7	4.8	18
128	Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 63, 149-55	3.5	25
127	Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. <i>International Journal of Hematology</i> , 2008 , 88, 374-380	2.3	11
126	Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. <i>Supportive Care in Cancer</i> , 2008 , 16, 1375-80	3.9	10
125	Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. <i>Cancer</i> , 2008 , 112, 260-7	6.4	99
124	Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. <i>Cancer</i> , 2008 , 113, 238-46	6.4	51
123	Supracricoid partial laryngectomies after radiation failure: a multi-institutional series. <i>Head and Neck</i> , 2008 , 30, 372-9	4.2	51

122	Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008 , 112, 4187-4187	2.2	1
121	Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008 , 112, 4158-4158	2.2	0
120	Standard Versus High Dose Lenograstim in Adults with Hematological Malignancies for Peripheral Blood Progenitor Cell Mobilization: Results of a Retrospective Study on Behalf of Rome Transplant Network.. <i>Blood</i> , 2008 , 112, 2302-2302	2.2	
119	Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. <i>Cancer</i> , 2007 , 110, 525-33	6.4	83
118	Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. <i>European Urology</i> , 2007 , 51, 576-7	10.2	4
117	Aromatase inhibitors in post-menopausal metastatic breast carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 1023-36	5.9	3
116	A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2117-23	2.5	11
115	Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 176; author reply 176-7	9.7	2
114	Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 605-6; author reply 606-7	2.2	3
113	Molecular analyses and prognostic relevance of HPV in head and neck tumours. <i>Oncology Reports</i> , 2007 ,	3.5	8
112	Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. <i>Thrombosis Research</i> , 2007 , 119, 525-9	8.2	2
111	Self-monitoring versus standard monitoring of oral anticoagulation. <i>Thrombosis Research</i> , 2007 , 119, 389-90	8.2	1
110	Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. <i>Cancer Investigation</i> , 2007 , 25, 102-5	2.1	31
109	Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007 , 110, 3093-3093	2.2	
108	Molecular analyses and prognostic relevance of HPV in head and neck tumours. <i>Oncology Reports</i> , 2007 , 17, 931-9	3.5	52
107	Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing. <i>Anticancer Research</i> , 2007 , 27, 2839-44	2.3	6
106	Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 615-23	3.5	20
105	Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. <i>European Journal of Haematology</i> , 2006 , 76, 51-7	3.8	9

104	Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. <i>Cancer</i> , 2006 , 106, 783-8	6.4	69
103	Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. <i>Cancer</i> , 2006 , 106, 2337-44	6.4	111
102	Chemotherapy-induced amenorrhea in early breast cancer. <i>Annals of Oncology</i> , 2006 , 17, 352	10.3	3
101	Does low-molecular-weight heparin influence cancer-related mortality?. <i>Annals of Oncology</i> , 2006 , 17, 1604-6	10.3	6
100	Factorial design for randomized clinical trials. <i>Annals of Oncology</i> , 2006 , 17, 1607-8	10.3	4
99	Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5618-9	2.2	2
98	Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3048-55	2.2	33
97	Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?. <i>Annals of Oncology</i> , 2006 , 17, 528-9	10.3	2
96	Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. <i>British Journal of Cancer</i> , 2006 , 94, 1789-96	8.7	27
95	Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with the extent of angiogenesis and disease-progression risk in early disease. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1034-40	1.9	11
94	An integrated psychological strategy for advanced colorectal cancer patients. <i>Health and Quality of Life Outcomes</i> , 2006 , 4, 9	3	13
93	Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. <i>Cancer Treatment Reviews</i> , 2006 , 32, 325-32	14.4	15
92	Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2006 , 32, 583-7	14.4	49
91	Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?. <i>Chest</i> , 2006 , 130, 1808-16	5.3	30
90	Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. <i>Anti-Cancer Drugs</i> , 2006 , 17, 1193-200	2.4	5
89	A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 64, 161-7	4	49
88	Chronic Lymphocytic Leukemia (CLL) in Parents and Children.. <i>Blood</i> , 2006 , 108, 4935-4935	2.2	
87	Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006 , 108, 2786-2786	2.2	

86	Clinical features and outcome of familial chronic lymphocytic leukemia. <i>Haematologica</i> , 2006 , 91, 1117-20.6		31
85	Gemcitabine treatment of experimental C6 glioma: the effects on cell cycle and apoptotic rate. <i>Anticancer Research</i> , 2006 , 26, 3017-24	2.3	9
84	O-120 Pooled-analysis of 6494 patients in 12 trials (1994-2004) receiving post-operative adjuvant chemotherapy in non-small cell lung cancer: Analyzing the magnitude of benefit in survival. <i>Lung Cancer</i> , 2005 , 49, S42	5.9	2
83	Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. <i>Oncology</i> , 2005 , 69, 35-43	3.6	107
82	Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome. <i>Journal of Chemotherapy</i> , 2005 , 17, 685-92	2.3	14
81	Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer. <i>Journal of Cellular Physiology</i> , 2005 , 204, 106-12	7	13
80	Long-term survival in locally advanced oral cavity cancer: an analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery. <i>Head and Neck</i> , 2005 , 27, 452-8	4.2	15
79	Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. <i>Cancer</i> , 2005 , 103, 672-9	6.4	39
78	Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. <i>Cancer</i> , 2005 , 104, 1237-45	6.4	30
77	New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. <i>Cancer</i> , 2005 , 104, 1335-42	6.4	32
76	Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. <i>Annals of Oncology</i> , 2005 , 16, 1498-502	10.3	11
75	Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?. <i>Gut</i> , 2005 , 54, 891	19.2	1
74	Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7248-50; author reply 7250	2.2	11
73	Treatment of resected non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 1523-4; author reply 1523-4	59.2	5
72	A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2005 , 46, 553-60	1.9	19
71	Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6908-18	2.2	79
70	Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 560-6	9.7	352
69	Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer. <i>Anticancer Research</i> , 2005 , 25, 1309-14	2.3	1

68	HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 568-9	2.2	5
67	Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. <i>Clinical Cancer Research</i> , 2004 , 10, 1360-5	12.9	37
66	Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions. <i>Glycobiology</i> , 2004 , 14, 783-92	5.8	29
65	Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. <i>European Journal of Haematology</i> , 2004 , 73, 36-42	3.8	22
64	High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004 , 130, 445-52 ⁴⁻⁹	4.9	3
63	Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. <i>Annals of Oncology</i> , 2004 , 15, 1065-71	10.3	42
62	Serum Insulinlike Growth Factor Is Not Elevated in Patients with Early B-Cell Chronic Lymphocytic Leukemia but Is Still a Prognostic Factor for Disease-Progression.. <i>Blood</i> , 2004 , 104, 4786-4786	2.2	
61	Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study. <i>Anticancer Research</i> , 2004 , 24, 1963-7	2.3	5
60	Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. <i>Annals of Oncology</i> , 2003 , 14, 1722-6	10.3	207
59	Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3462-8	2.2	61
58	Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2003 , 70, 373-8	3.8	37
57	Can patient selection for bladder preservation be based on response to chemotherapy?. <i>Cancer</i> , 2003 , 97, 1644-52	6.4	110
56	Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. <i>Cancer</i> , 2003 , 98, 337-43	6.4	44
55	Cutaneous response to irritants. <i>Contact Dermatitis</i> , 2003 , 48, 69-73	2.7	6
54	Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. <i>Annals of Oncology</i> , 2003 , 14, 1378-82	10.3	46
53	Re: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1719-20; author reply 1721-2	9.7	
52	First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2689-94	2.2	29
51	Antimicrobial action of Nitens mouthwash (cetyltrimethylammonium naproxenate) on multiple isolates of pharyngeal microbes: a controlled study against chlorhexidine, benzydamine, hexetidine, amoxicillin, amoxicillin-clavulanate, clarithromycin, and cefaclor. <i>Chemotherapy</i> , 2002 , 48, 168-73	3.2	5

50	Neoadjuvant Chemotherapy and Radical Surgery Versus Exclusive Radiotherapy in Locally Advanced Squamous Cell Cervical Cancer: Results From the Italian Multicenter Randomized Study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 179-188	2.2	249
49	Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone. <i>Haematologica</i> , 2002 , 87, 602-8	6.6	4
48	Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2002 , 87, 926-33	6.6	21
47	Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. <i>Cancer</i> , 2001 , 92, 713-9	6.4	26
46	Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. <i>Anti-Cancer Drugs</i> , 2000 , 11, 495-507	4	17
45	Prognostic relevance of altered Fas (CD95)-system in human breast cancer. <i>International Journal of Cancer</i> , 2000 , 89, 127-32	7.5	85
44	Treatment of peritoneal carcinomatosis with intent to cure. <i>Journal of Surgical Oncology</i> , 2000 , 74, 41-4	2.8	65
43	Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy pattern, histopathology, and clinical outcome. <i>International Journal of Clinical and Laboratory Research</i> , 2000 , 30, 5-11		4
42	Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. <i>Blood</i> , 2000 , 95, 2786-2792	2.2	228
41	Peritonectomy and hyperthermic antitumor perfusion in the treatment of peritoneal carcinomatosis. <i>European Journal of Surgical Oncology</i> , 2000 , 26, 486-91	3.6	29
40	Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000 , 23, 132-9	2.7	37
39	Clinical Characteristics and Outcome of Young Chronic Lymphocytic Leukemia Patients: A Single Institution Study of 204 Cases. <i>Blood</i> , 1999 , 94, 448-454	2.2	178
38	Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women. <i>Breast Cancer Research and Treatment</i> , 1999 , 55, 259-66	4.4	12
37	Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. <i>Annals of Oncology</i> , 1999 , 10, 937-42	10.3	27
36	Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. <i>Annals of Oncology</i> , 1999 , 10, 1301-5	10.3	35
35	Hyperthermic antitumor perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. <i>Journal of Immunotherapy</i> , 1999 , 22, 407-14	5	22
34	The application of hyperthermia in regional chemotherapy. <i>Journal of Surgical Oncology</i> , 1998 , 14, 215-23		20
33	Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 42, 1119-26	4	113

32	Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. <i>Journal of Clinical Oncology</i> , 1998 , 16, 3406-11	2.2	91
31	Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. <i>Journal of Clinical Oncology</i> , 1998 , 16, 86-92	2.2	115
30	Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. <i>Urology</i> , 1997 , 49, 786-9	1.6	47
29	Inpatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. <i>European Journal of Cancer</i> , 1995 , 31A, 1611-4	7.5	12
28	Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995 , 1, 127-33	2.8	11
27	High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: a pilot study. <i>Cancer Investigation</i> , 1994 , 12, 574-87	2.1	4
26	Improved local control and survival with the "sandwich" technique of pelvic radiotherapy for resectable rectal cancer. A retrospective, multivariate analysis. <i>Diseases of the Colon and Rectum</i> , 1994 , 37, S6-15	3.1	
25	Nerve-sparing surgery in 302 resectable rectosigmoid cancer patients: genitourinary morbidity and 10-year survival. <i>Diseases of the Colon and Rectum</i> , 1994 , 37, S42-6	3.1	38
24	Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases. <i>Diseases of the Colon and Rectum</i> , 1994 , 37, S138-43	3.1	9
23	Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck. <i>European Journal of Cancer</i> , 1994 , 30A, 928-30	7.5	8
22	Use of discriminant analysis to assess disease activity in pulmonary tuberculosis with a panel of specific and nonspecific serum markers. <i>American Journal of Clinical Pathology</i> , 1994 , 101, 719-25	1.9	15
21	Flow cytometric analysis of ploidy in colorectal cancer: a multicentric experience. <i>British Journal of Cancer</i> , 1993 , 67, 1042-6	8.7	23
20	Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. <i>Cancer</i> , 1993 , 72, 1975-82	6.4	50
19	Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. <i>Journal of Clinical Oncology</i> , 1992 , 10, 378-82	2.2	106
18	Hyperthermic antitumor perfusion in the treatment of local recurrence or "in-transit" metastases of limb melanoma. <i>Journal of Surgical Oncology</i> , 1992 , 8, 374-80		9
17	Definitive radiation therapy for localized prostatic adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991 , 20, 439-46	4	17
16	Tumor progression in human malignant melanoma is associated with changes in alpha 6/beta 1 laminin receptor. <i>International Journal of Cancer</i> , 1991 , 49, 168-72	7.5	42
15	Transurethral resection of the prostate and metastatic prostate cancer. <i>Cancer</i> , 1991 , 68, 1895-8	6.4	15

14	Radical surgery in rectal cancer patients: what does it mean today?. <i>Journal of Surgical Oncology</i> , 1991 , 2, 24-31	2.8	7
13	Detection of Helicobacter pylori carriers by discriminant analysis of urea and pH levels in gastric juices. <i>Journal of Clinical Pathology</i> , 1991 , 44, 697-8	3.9	8
12	Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. <i>Journal of Clinical Oncology</i> , 1991 , 9, 432-7	2.2	82
11	High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. <i>British Journal of Haematology</i> , 1990 , 75, 373-7	4.5	42
10	N-methylformamide affects spontaneous metastases of 3LL lines and increases natural killer activity of tumor-bearing mice. <i>Clinical and Experimental Metastasis</i> , 1990 , 8, 153-63	4.7	7
9	Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. <i>Journal of Clinical Oncology</i> , 1989 , 7, 829-37	2.2	70
8	Multivariate analysis of a tissue CEA, TPA, and CA 19.9 quantitative study in colorectal cancer patients. A preliminary finding. <i>Diseases of the Colon and Rectum</i> , 1989 , 32, 389-97	3.1	20
7	Prognostic variables in recurrent limb melanoma treated with hyperthermic antineoplastic perfusion. <i>Cancer</i> , 1989 , 63, 2551-61	6.4	107
6	Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. <i>Cancer</i> , 1989 , 64, 1117-22	6.4	90
5	A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. <i>Cancer</i> , 1989 , 64, 2431-6	6.4	43
4	The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. <i>Radiotherapy and Oncology</i> , 1989 , 14, 95-101	5.3	92
3	Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989 , 12, 524-9	2.7	17
2	Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer. <i>Cancer</i> , 1988 , 62, 251-61	6.4	35
1	Acute leukaemia in patients treated for Hodgkin's disease. <i>British Journal of Haematology</i> , 1984 , 58, 43-52	5	51